Boulder, CO – According to filings with the U.S. Securities and Exchange Commission, Accure Acne is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Christopher Carlton played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Accure Acne
At Accure, we are wholly committed to developing revolutionary solutions to provide a long-lasting, durable response to acne. We know that acne can have a devastating social, psychological, physical, and economic impact on patients around the world. We are pioneering transformative solutions that will answer this unmet need and have a positive and profound impact on patients and providers worldwide. Accure is committed to developing a novel and impactful solution for acne sufferers that employs a revolutionary technology designed to improve their long-term quality of life. Accure is committed to developing a truly differentiated and protected product for clinicians worldwide. Accures clinical and technical team is uniquely impressive. The Accure device has been granted CE Mark approval which allows Accure to commercialize in the European Union, while creating a global and exclusive intellectual property portfolio. Accure is committed to developing a uniquely compelling value proposition. Accure has developed a clear and compelling go-to-market strategy, leveraging significant commercialization experience and regulatory expertise.

To learn more about Accure Acne, visit http://www.accureacne.com/

Contact:
Christopher Carlton, Chief Executive Officer
970-688-2498
ccarlton@accureacne.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved